All subjects
Biochemicals & Materials

MYM enters into pot research partnership with the University of Sherbrooke

In Canada, MYM Nutraceuticals Inc., a Vancouver-headed focused on acquiring Health Canada licenses to produce and sell medicinal cannabis supplements and products has announced that it has entered into a partnership with the University of Sherbrooke in Québec to study the medicinal and industrial uses of cannabis and hemp. Researchers at the University of Sherbrooke will work with an on-site coordinator to create partnerships by targeting expertise in various faculties and training centres.

Professor Jean-Pierre Perreault (left) Vice-President, Research, Partnerships and Entrepreneurship, Université de Sherbrooke; Rob Gietl, CEO, MYM Nutraceuticals; Serge Beaudoin, Director Business Partnership Group, Université de Sherbrooke and Charith Adkar, CSO, MYM Nutraceuticals (photo courtesy François Lafrance / Université de Sherbrooke).

Subject to provincial or territorial restrictions, the recently passed Cannabis Act that comes into force on October 17, 2018, aims to provide a strict legal framework for controlling the production, distribution, sale, and possession of cannabis across Canada.

During cannabis prohibition, research on its compounds and by-products remained very limited. according to a joint statement, this partnership aims to explore the benefits of the cannabis plant.

The signing of this partnership agreement with the University of Sherbrooke furthers our goal to be at the forefront of cannabis plant research and development. Furthermore, I am delighted to see our company associated with a large Québec university that has an outstanding reputation in research and innovation, said Rob Gietl, CEO of MYM Nutraceuticals.

Avenues of collaboration range from identifying the best alternative energy systems in greenhouses to the effects of cannabinoids on the nervous and immune systems. The research will also include industrial materials manufacturing, eco-materials, hemp fibre biofuels and opportunities created from the by-products of cannabis production.

Université de Sherbrooke groups together a broad set of skills in relation to the opportunities associated with cannabis. MYM’s contribution will help actively explore multiple research projects. This is a completely new and highly promising multidisciplinary partnership we wish to nurture and grow in the coming years said Vincent Aimez, Vice-President, Commercialization, and Partnerships, University of Sherbrooke.

The University of Sherbrooke is at the heart of one of Quebec’s three major research poles. Known for its spirit of innovation, the university partners with all levels of government to promote social, cultural and economic development and excels in technology transfer and initiatives focused on entrepreneurship and innovation in collaboration with the industrial and social communities.

I believe that this innovative agreement with the University of Sherbrooke will allow our company to achieve its objectives in research and development in connection with our medical cannabis-based products. We have much to do to demonstrate the relevance of prescribing medical cannabis to deal with health problems. In this respect, research is an important lever to show the usefulness of our products relative to health issues, said Charith Adkar, Chief Science Officer at MYM Nutraceuticals.



MYM Nutraceuticals is a shareholder in two production projects in Quebec that are anticipated to have over 1.5 million square feet of production space. The company is also a shareholder in two additional cannabis production projects in Australia and Colombia. The “Northern Rivers Project” in New South Wales, Australia is expected to have 1.2 million square feet of cannabis production space. In Colombia, its partner, Colombia Organica, currently hold a seed to sale license for low Tetrahydrocannabinol (THC) cannabis and are in the licensing process for the cultivation and production of high THC cannabis extracts. Plans are underway to build a cannabis production facility in the region. To ensure a strong presence and growth potential within the industry, the company is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals, and cannabidiol (CBD) sectors.

Most read on Bioenergy International

Get the latest news about Bioenergy

Subscribe for free to our newsletter
Sending request
I accept that Bioenergy International stores and handles my information.
Read more about our integritypolicy here